Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
m |
||
| Line 32: | Line 32: | ||
|- | |- | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
| − | | style="background-color:#1a9851" |Phase III (E) | + | | style="background-color:#1a9851" |Phase III (E-de-esc) |
|[[#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | |[[#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | ||
| style="background-color:#eeee01" |Non-inferior complete resection rate | | style="background-color:#eeee01" |Non-inferior complete resection rate | ||
| Line 51: | Line 51: | ||
===Regimen {{#subobject:c48515|Variant=1}}=== | ===Regimen {{#subobject:c48515|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| − | !style="width: | + | !style="width: 20%"|Study |
| − | !style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| − | !style="width: | + | !style="width: 20%"|Comparator |
| − | !style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
| + | !style="width: 20%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]] | ||
|- | |- | ||
|[https://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | |[https://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | ||
| − | | style="background-color:#1a9851" |Phase III (E) | + | | style="background-color:#1a9851" |Phase III (E-switch-ic) |
|Cisplatin, 5-FU, Vincristine | |Cisplatin, 5-FU, Vincristine | ||
| − | | style="background-color:# | + | | |
| + | | style="background-color:#d73027" |More toxic | ||
|- | |- | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
| Line 65: | Line 67: | ||
|[[#Cisplatin_monotherapy|Cisplatin]] | |[[#Cisplatin_monotherapy|Cisplatin]] | ||
| style="background-color:#eeee01" |Non-inferior complete resection rate | | style="background-color:#eeee01" |Non-inferior complete resection rate | ||
| + | | | ||
|- | |- | ||
|} | |} | ||
Revision as of 03:58, 4 December 2019
| Section editor | |
|---|---|
 |
Wayne H. Liang, MD, MS UAB Birmingham, AL  WayneLiangMD
|
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (E-de-esc) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin & Doxorubicin
| back to top |
PLADO: PLAtinol (Cisplatin) & DOxorubicin
Regimen
| Study | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
|---|---|---|---|---|
| Ortega et al. 2000 | Phase III (E-switch-ic) | Cisplatin, 5-FU, Vincristine | More toxic | |
| Perilongo et al. 2009 (SIOPEL 3) | Phase III (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed